Acacia Pharma Group plc Acacia Pharma Group Plc: Notice Of Annual General Meeting
26 5월 2021 - 1:00AM
UK Regulatory
TIDMACPH
Acacia Pharma Group plc: Notice of Annual General Meeting
Cambridge, UK and Indianapolis, US -- 25 May 2021 Acacia Pharma Group
plc ("Acacia Pharma", the "Company") (EURONEXT: ACPH), a hospital
pharmaceutical company focused on the development and commercialization
of new products aimed at improving the care of patients undergoing
significant treatments such as surgery, other invasive procedures or
cancer chemotherapy, announces that its annual general meeting of
shareholders ("AGM") will be held at 2:00pm BST on Monday 28 June 2021
at the offices of Acacia Pharma Inc, 8440 Allison Pointe Boulevard,
Suite 100, Indianapolis, IN 46250, United States.
The formal notice convening the AGM (including agenda, information on
attending the meeting in person or by proxy, requirements for
notification and registration for the meeting) together with the Form of
Proxy, and the Company's Annual Report and Accounts for the year ended
31 December 2020, will be posted to shareholders today and are available
from today on the Company's website www.acaciapharma.com in the
Investors/Shareholder Meetings section and the Investors/Financial
Reports section, respectively.
Contacts
Acacia Pharma Group plc International Media
Mike Bolinder, CEO Mark Swallow, Frazer Hall, David
Gary Gemignani, CFO Dible
+44 1223 919760 / +1 317 505 1280 Citigate Dewe Rogerson
IR@acaciapharma.com +44 20 7638 9571
acaciapharma@citigatedewerogerson.com
US Investors Media in Belgium and the Netherlands
LifeSci Advisors Chris Van Raemdonck
Irina Koffler +32 499 58 55 31
+1 917-734-7387 chrisvanraemdonck@telenet.be
ikoffler@lifesciadvisors.com
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the
development and commercialization of new products aimed at improving the
care of patients undergoing significant treatments such as surgery,
other invasive procedures, or cancer chemotherapy. The Company has
identified important and commercially attractive unmet needs in these
areas that its product portfolio aims to address.
Acacia Pharma's first product, BARHEMSYS(R) (amisulpride injection) is
available in the US for the management of postoperative nausea &
vomiting (PONV).
BYFAVO(TM) (remimazolam) for injection, a very rapid onset/offset IV
benzodiazepine sedative is approved and launched in the US for use
during invasive medical procedures in adults lasting 30 minutes or less,
such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion
UK Limited for the US market.
APD403 (intravenous and oral amisulpride), a selective dopamine
antagonist for chemotherapy induced nausea & vomiting (CINV) has
successfully completed one proof-of-concept and one Phase 2 dose-ranging
study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D
operations are centred in Cambridge, UK. The Company is listed on the
Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker
symbol ACPH.
Acacia Pharma Group plc
The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United
Kingdom
Company number 9759376
www.acaciapharma.com
(END) Dow Jones Newswires
May 25, 2021 12:00 ET (16:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Acacia Pharma (LSE:0PNT)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Acacia Pharma Group Plc (London Stock Exchange)의 실시간 뉴스: 최근 기사 0
More Acacia Pharma Group Plc News Articles